Today, Achaogen’s (AKAO) “Outperform” Rating Reiterate at Wedbush

Today, Achaogen’s (AKAO) “Outperform” Rating Reiterate at Wedbush
Wedbush reaffirmed their outperform rating on shares of Achaogen Inc. (NASDAQ:AKAO) in a report issued on Tuesday. Wedbush currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on AKAO. Zacks Investment Research lowered shares of Achaogen from a buy rating to a hold rating in a report on Thursday, August 11th. Cowen and Company reiterated a hold rating on shares of Achaogen in a report on Tuesday, November 8th. Aegis began coverage on shares of Achaogen in a report on Wednesday, November 2nd. They set a buy rating and a $10.00 price objective on the stock. Needham & Company LLC reiterated a hold rating on shares of Achaogen in a report on Tuesday, August 9th. Finally, SunTrust Banks Inc. reiterated a buy rating and set a $10.00 price objective on shares of Achaogen in a report on Monday, September 26th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $8.63.

Achaogen (NASDAQ:AKAO) opened at 4.93 on Tuesday. Achaogen has a 12-month low of $2.59 and a 12-month high of $6.18. The company’s market cap is $135.33 million. The company’s 50-day moving average price is $4.87 and its 200-day moving average price is $4.12.

Achaogen (NASDAQ:AKAO) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.20. Achaogen had a negative net margin of 147.80% and a negative return on equity of 143.44%. The firm had revenue of $16.05 million for the quarter, compared to analyst estimates of $8.72 million. During the same quarter in the prior year, the business earned ($0.48) earnings per share. The business’s quarterly revenue was up 258.3% compared to the same quarter last year. Equities analysts anticipate that Achaogen will post ($2.31) earnings per share for the current year.

Several large investors have recently bought and sold shares of AKAO. Sphera Funds Management LTD. purchased a new stake in shares of Achaogen during the third quarter worth about $6,228,000. Spark Investment Management LLC increased its stake in shares of Achaogen by 852.7% in the third quarter. Spark Investment Management LLC now owns 143,865 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 128,765 shares during the last quarter. Northern Trust Corp increased its stake in shares of Achaogen by 52.6% in the third quarter. Northern Trust Corp now owns 23,346 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 8,046 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of Achaogen by 241.4% in the second quarter. Point72 Asset Management L.P. now owns 890,000 shares of the biopharmaceutical company’s stock worth $3,373,000 after buying an additional 629,309 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Achaogen during the second quarter worth about $142,000. Institutional investors own 55.96% of the company’s stock.

Achaogen Company Profile

Related posts

Leave a Comment